Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
VCVericel Corporation logo

Vericel Corporation (VCEL)

NASDAQ Capital Market · Currency in USD
$42.53 ▼ -0.44 (-1.02%)
At close: Oct 23, 4:00 PM ET. Market closed.
$42.53 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$42.97
Open
$42.42
Day's Range
$42.07 – $42.90
52 Week Range
$28.95 – $49.32
Volume
494,729
Avg. Volume
555,497
Market Cap
$2.18B
Beta (5Y Monthly)
1.03
PE Ratio (TTM)
88.60
EPS (TTM)
$0.48
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$60.67

Profile: Vericel Corporation

Sector
Healthcare
Industry
Biotechnology
Full-time employees
398
CEO
Dominick C. Colangelo
Website
vcel.com

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate $0.06 · Revenue est. $77.95M
DateEst.Actual
Jul 30, 2026-$0.03$0.04Beat
May 7, 2026-$0.15-$0.12Beat
Feb 26, 2026$0.45$0.45Beat
Nov 6, 2025-$0.02$0.10Beat
Jul 31, 2025-$0.04-$0.01Beat
May 8, 2025-$0.09-$0.23Miss

Analyst view

Consensus price target
$60.67 ▲ +42.7%
Range $52.00 – $70.00
Rating: Buy
Buy 64% · Hold 36% · Sell -0%

Get free alerts on VCEL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.